17-43071077-T-A
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 2P and 10B. PM5BP4_ModerateBP6_Very_Strong
The NM_007294.4(BRCA1):c.4837A>T(p.Ser1613Cys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000304 in 1,613,874 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 12/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S1613A?) has been classified as Pathogenic.
Frequency
Consequence
NM_007294.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BRCA1 | NM_007294.4 | c.4837A>T | p.Ser1613Cys | missense_variant | 15/23 | ENST00000357654.9 | NP_009225.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BRCA1 | ENST00000357654.9 | c.4837A>T | p.Ser1613Cys | missense_variant | 15/23 | 1 | NM_007294.4 | ENSP00000350283 | P4 |
Frequencies
GnomAD3 genomes AF: 0.000184 AC: 28AN: 151990Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000517 AC: 13AN: 251384Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135858
GnomAD4 exome AF: 0.0000144 AC: 21AN: 1461884Hom.: 0 Cov.: 59 AF XY: 0.0000124 AC XY: 9AN XY: 727240
GnomAD4 genome AF: 0.000184 AC: 28AN: 151990Hom.: 0 Cov.: 32 AF XY: 0.000243 AC XY: 18AN XY: 74216
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Benign:3
Likely benign, criteria provided, single submitter | curation | Sema4, Sema4 | Jul 07, 2021 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Oct 06, 2016 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 01, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Breast-ovarian cancer, familial, susceptibility to, 1 Uncertain:1Benign:1
Uncertain significance, no assertion criteria provided | clinical testing | Breast Cancer Information Core (BIC) (BRCA1) | Feb 20, 2004 | - - |
Benign, no assertion criteria provided | clinical testing | Sharing Clinical Reports Project (SCRP) | Nov 14, 2011 | - - |
not specified Benign:2
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Mar 11, 2024 | Variant summary: BRCA1 c.4837A>T (p.Ser1613Cys) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 5.2e-05 in 251384 control chromosomes, predominantly at a frequency of 0.0008 within the African or African-American subpopulation in the gnomAD database. This frequency is not significantly higher than estimated for a pathogenic variant in BRCA1 causing Hereditary Breast And Ovarian Cancer Syndrome (5.2e-05 vs 0.001), allowing no conclusion about variant significance. c.4837A>T has been reported in the literature in individuals affected with Breast And Ovarian Cancer Syndrome (Majdak_2005, D'Argenio_2015, Cifuentes-C_2019, Cecener_2020). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. At least one publication reports experimental evidence evaluating an impact on protein function and showed that this variant is likely not pathogenic (Woods_2016, Fernandes_2019). The following publications have been ascertained in the context of this evaluation (PMID: 18992264, 31706072, 32284662, 15004537, 25896959, 30765603, 15617999, 9326340, 15350310, 28781887). ClinVar contains an entry for this variant (Variation ID: 37613). Based on the evidence outlined above, the variant was classified as likely benign. - |
Benign, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Apr 18, 2019 | - - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Dec 18, 2020 | This variant is associated with the following publications: (PMID: 26092435, 31705708, 15004537, 15350310, 19370767, 10728701, 21447777, 18992264, 25896959, 15617999, 9326340, 26183948, 28781887, 30765603, 31706072) - |
Malignant tumor of breast Benign:1
Likely benign, no assertion criteria provided | clinical testing | Department of Pathology and Laboratory Medicine, Sinai Health System | - | The BRCA1 p.Ser1613Cys variant was identified in 1 of 140 proband chromosomes (frequency: 0.007) from individuals or families with breast cancer (D'Argenio 2015). The variant was also identified in dbSNP (rs1799966) as “other”, in ClinVar with conflicting interpretations of pathogenicity (5 submitters, classified as Likely Benign by Invitae, Ambry, and GeneDx, classified as Uncertain Significance by BIC and as Benign by the Sharing Clinic Reports Project), in Clinvitae (classified as Likely benign as reported in ClinVar) and in BIC (4x classified as unknown), the Fanconi Anemia Mutation Database (3x classified as predicted neutral) databases. The variant was also identified in the control database the Exome Aggregation Consortium (ExAC) in 8 of 121360 chromosomes (freq. 0.00007), all cases were seen in the African population specifically 8 of 10406 chromosomes (freq. 0.0008), increasing the likelihood that this may be a low frequency benign variant. The variant was not identified in the 1000 Genomes Project, the NHLBI GO Exome Sequencing Project, the ARUP Laboratories BRCA Mutations Database, COSMIC, GeneInsight COGR, and UMD. Functional studies initially reported the p.Ser1613Cys variant to be disease causing based on a transcription activation assay performed in yeast (Monteiro 1997). However a more recent and more sensitive transcriptional assay reported the p.Ser1613Cys variant to be likely neutral and noted that the sensitivity of the previous assay was likely the reason for the conflicting results (Carvalho 2009). The p.Ser1613 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. Moreover this locus is the known site of a common polymorphism in BRCA1 p.Ser1613Gly (identified in 35% of cases in ExAC) and classified as Benign by our laboratory. The variant occurs outside of the splicing consensus sequence and 1 of 5 in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predict a greater than 10% difference in splicing; this is not very predictive of pathogenicity. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign. - |
BRCA1-related disorder Benign:1
Likely benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Oct 01, 2021 | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Hereditary breast ovarian cancer syndrome Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 21, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at